2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
Marina Cuchel(University of Pennsylvania), Kausik K. Ray(Imperial College London), Klaus G. Parhofer(LMU Klinikum), Lâle Tokgözoğlu(Hacettepe University), Mariko Harada‐Shiba(Osaka University of Pharmaceutical Sciences), Jane K. Stock(European Atherosclerosis Society), Khalid Al‐Rasadi(Sultan Qaboos University Hospital), Robert A. Hegele(Western University), Jeanine E. Roeters van Lennep(Erasmus MC), Frederick J. Raal(University of the Witwatersrand), Raúl D. Santos(Universidade de São Paulo), Éric Bruckert(Centre de Recherche Médecine, Sciences, Santé, Santé Mentale, Société), L. Masana(Universitat Rovira i Virgili), Tomáš Freiberger(Masaryk University), Maurizio Averna(Instituto di Biofisica), Marcello Arca(Sapienza University of Rome), Gerald F. Watts(Royal Perth Hospital), Erik S.G. Stroes(Amsterdam University Medical Centers), Daniel Gaudet(Brigham and Women's Hospital), Alberico L. Catapano(University of Milan), Meral Kayıkçıoğlu, Lisa C. Hudgins(Cornell University), Albert Wiegman(Amsterdam University Medical Centers)
Cited by 329
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
Atherosclerosis
|Nature Reviews Disease Primers|2019|3k